Overview

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy (TrustTSC OLE)

Status:
Enrolling by invitation

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001

Phase:

Phase 3

Details

Lead Sponsor:

Marinus Pharmaceuticals

Treatments:

Ganaxolone